RESULTS _ CONCLUSION : In patients adherent to tamoxifen for at least one year ( n = 313 ) there was an association between reduced CYP2D6 activity ( < = 50 % of normal ) and recurrence ( p = 0.025 ) and breast cancer -specific mortality ( p = 0.034 ) .